What an NCD Would Actually Mean for Wound Care

Coverage in wound care has never been been applied consistently. Local Coverage Determinations vary by region, Medicare Advantage plans apply their own interpretations, and the same treatment can be handled differently depending on where and how it is billed.

A National Coverage Determination introduces a baseline. It establishes a single reference point that everything else builds from. With an NCD in place, expectations become clearer across wound care, and that clarity changes how decisions are made, documented, and defended. 

The push for a national framework comes from a mismatch that has been building for years. The body of data around advanced wound therapies has grown significantly, yet formal coverage structures remain concentrated around diabetic foot ulcers and venous leg ulcers. Pressure injuries, surgical wounds, and other complex wound types often remain in a less defined space, even where clinicians have seen strong outcomes.

At the same time, the evidence generated in wound care does not always match the evidence hierarchy that drives coverage decisions. Randomized controlled trials continue to carry the most weight, while much of the usable data in this field comes from real-world outcomes across diverse patients, wound types, and care settings.

That disconnect has contributed to the environment our industry is operating in now: utilization growth, uneven documentation, scrutiny from payers and regulators, and meaningful variation in access depending on geography and plan structure.

A national framework is being advanced as a way to bring those moving parts into closer alignment, not by removing complexity, but by defining the terms under which it operates.

What Changes in Practice 

The first meaningful change would show up at the physician level. Right now, treatment decisions are often made in an environment where coverage may exist, but the boundaries around that coverage are interpreted differently across regions and payers. That uncertainty influences how confidently physicians treat, how broadly they apply advanced therapies, and how much risk they are willing to carry in the process.

A national framework does not remove clinical judgment, but it gives that judgment a clearer operating structure. Defined entry criteria, clearer documentation expectations, and more consistent clinical standards create a reference point that can travel across regions instead of resetting every time the payer mix changes. CMS has described the NCD process in those terms, as a way to create more predictable and transparent coverage decisions.

That consistency could also broaden what can be treated. If the framework becomes more etiology-inclusive, pressure injuries, surgical wounds, and other complex cases move into a more defined clinical and reimbursement structure instead of remaining in gray areas.

That same clarity matters when a case is reviewed. Audits are not driven by coverage alone. The real question in review is whether the care delivered matches the governing criteria and whether the documentation supports that decision.

When standards vary, the defense of a claim often becomes a matter of interpretation. When standards are clearer, the posture of review changes.

A national policy provides a more stable reference point against which cases can be judged, even as audits, contractor oversight, and Medicare Advantage utilization management remain. Other areas of healthcare have shown that National Coverage Determinations can improve consistency in coverage criteria without eliminating variation in review or control. The benefit is greater consistency in how complexity is managed.

Where This Leads

How clinical evidence is evaluated will continue to shape coverage decisions in wound care. 

Randomized controlled trials will continue to matter because CMS has historically treated stronger clinical evidence as foundational to medical necessity decisions, but wound care is a field that generates substantial real-world data from a range of wound types, patient variables, and care environments involved.

More recent proposals have tried to close that gap by outlining tiered approaches that incorporate both randomized trials and real-world evidence, allowing coverage and payment to reflect the actual strength and form of the available data rather than forcing every product into a single evidentiary mold. That does not lower the standard. It makes the standard more applicable to how wound care is actually practiced.

For the industry, the shift is less about changing the structure of care and more about clarifying expectations within it. Physicians will be working within more defined clinical and documentation boundaries. Manufacturers will face clearer requirements around evidence generation and positioning. Access may expand, but within a framework that is applied more consistently.

That changes where the pressure lives. The differentiator becomes execution—how well decisions align with defined criteria, how consistently those decisions are documented, and how clearly they can be supported under review.

An NCD does not remove complexity from wound care. It gives that complexity a more stable structure, and this is where Bionavix is focused. Helping practices interpret how coverage is being applied in real settings, working through documentation and case strategy before exposure builds, and supporting decisions that need to hold up beyond the point of care. 

From there, the outcome depends on how well providers operate within it.